Postprandial gallbladder emptying in patients with type 2 diabetes: Potential implications for bile-induced secretion of glucagon-like peptide 1

European Journal of Endocrinology

Volumn 171, Issue 4, 2014, Pages 407-419

  Sonne, David P ^a   Rehfeld, Jens F ^b   Holst, Jens J ^a   Vilsbøll, Tina ^a   Knop, Filip K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; BIOLOGICAL MARKER; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BILE; CLINICAL ARTICLE; CONTROLLED STUDY; FAT CONTENT; FAT INTAKE; FEMALE; GALLBLADDER CONTRACTION; GALLBLADDER EMPTYING; GALLBLADDER MOTILITY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; INSULIN BLOOD LEVEL; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; STOMACH EMPTYING; AREA UNDER THE CURVE; BLOOD; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; DENMARK; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS);

ADULT; AGED; AREA UNDER CURVE; BILE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-PEPTIDE; CASE-CONTROL STUDIES; CHOLECYSTOKININ; DENMARK; DIABETES MELLITUS, TYPE 2; DIETARY FATS; FEMALE; GALLBLADDER EMPTYING; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GASTRINS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84907197676     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0309     Document Type: Article

References (50)

1. Namba M, Matsuyama T, Nonaka K & Tarui S. Effect of intraluminal bile or bile acids on release of gut glucagon-like immunoreactive materials in the dog. Hormone and Metabolic Research 1983 15 82-84. (doi:10.1055/s-2007-1018635)
2. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 2009 10 167-177. (doi:10.1016/j.cmet.2009.08.001)
3. Lefebvre P, Cariou B, Lien F, Kuipers F & Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiological Reviews 2009 89 147-191. (doi:10.1152/physrev.00010.2008)
4. Nauck M, Stöckmann F, Ebert R & Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986 29 46-52. (doi:10.1007/BF02427280)
5. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews 2007 87 1409-1439. (doi:10.1152/physrev.00034.2006)
6. Calanna S, Christensen M, Holst JJ, Laferrère B, Gluud LL, Vilsbøll T & Knop FK. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013 56 965-972. (doi:10.1007/s00125-013-2841-0)
7. Højberg PV, Vilsbøll T, ZanderM, Knop FK, Krarup T, Vølund A, Holst JJ & Madsbad S. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with type 2 diabetes. Diabetic Medicine 2008 25 1268-1275. (doi:10.1111/j.1464-5491.2008.02579.x)
8. Toft-Nielsen MB, Madsbad S & Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2001 86 3853-3860. (doi:10.1210/jcem.86.8.7743)
9. Vilsbøll T, Krarup T, Deacon CF, Madsbad S & Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001 50 609-613. (doi:10.2337/diabetes.50.3.609)
10. Vilsbøll T, Krarup T, Madsbad S & Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regulatory Peptides 2003 114 115-121. (doi:10.1016/S0167-0115(03)00111-3)
11. Fukase N, Manaka H, Sugiyama K, Takahashi H, IgarashiM, DaimonM, Yamatani K, Tominaga M & Sasaki H. Response of truncated glucagonlike peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Acta Diabetologia 1995 32 165-169. (doi:10.1007/BF00838486)
12. Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ & Krarup T. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007 56 1951-1959. (doi:10.2337/db07-0100)
13. Knop FK, Vilsbøll T, Madsbad S, Holst JJ & Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007 50 797-805. (doi:10.1007/s00125-006-0566-z)
14. Orskov C, Jeppesen J, Madsbad S & Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. Journal of Clinical Investigation 1991 87 415-423. (doi:10.1172/JCI115012)
15. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K & Egan JM. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. American Journal of Physiology. Endocrinology and Metabolism 2006 290 E550-E559. (doi:10.1152/ajpendo.00326.2004)
16. Vollmer K, Holst JJ, Baller B, EllrichmannM, Nauck MA, Schmidt WE & Meier JJ. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008 57 678-687. (doi:10.2337/db07-1124)
17. Pazzi P, Scagliarini R, Gamberini S & Pezzoli A. Review article: Gall-bladder motor function in diabetes mellitus. Alimentary Pharmacology & Therapeutics 2000 14 62-65. (doi:10.1046/j.1365-2036.2000.014s2062.x)
18. Shaw SJ, Hajnal F, Lebovitz Y, Ralls P, Bauer M, Valenzuela J & Zeidler A. Gallbladder dysfunction in diabetes mellitus. Digestive Diseases and Sciences 1993 38 490-496. (doi:10.1007/BF01316504)
19. Stone BG, Gavaler JS, Belle SH, Shreiner DP, Peleman RR, Sarva RP, Yingvorapant N & Van Thiel DH. Impairment of gallbladder emptying in diabetes mellitus. Gastroenterology 1988 95 170-176.
20. Güliter S, Yilmaz S & Karakan T. Evaluation of gallbladder volume and motility in non-insulin-dependent diabetes mellitus patients using real-time ultrasonography. Journal of Clinical Gastroenterology 2003 37 288-291. (doi:10.1097/00004836-200310000-00005)
21. Bucceri AM, Calogero AE & Brogna A. Gallbladder and gastric emptying: relationship to cholecystokininemia in diabetics. European Journal of Internal Medicine 2002 13 123-128. (doi:10.1016/S0953-6205(02)00003-1)
22. Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? American Journal of Physiology. Endocrinology and Metabolism 2010 299 E10-E13. (doi:10.1152/ajpendo.00137.2010)
23. Stone BG, Ansel HJ, Peterson FJ & Gebhard RL. Gallbladder emptying stimuli in obese and normal-weight subjects. Hepatology 1992 15 795-798. (doi:10.1002/hep.1840150508)
24. Dodds WJ, Groh WJ, Darweesh RM, Lawson TL, Kishk SM & Kern MK. Sonographic measurement of gallbladder volume. American Journal of Roentgenology 1985 145 1009-1011. (doi:10.2214/ajr.145.5.1009)
25. Everson GT, Braverman DZ, Johnson ML & Kern F. A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology 1980 79 40-46.
26. Krarup T & Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regulatory Peptides 1984 9 35-46. (doi:10.1016/0167-0115(84)90005-3)
27. Orskov C, Rabenhøj L, Wettergren A, Kofod H & Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagonlike peptide I in humans. Diabetes 1994 43 535-539. (doi:10.2337/diab.43.4.535)
28. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clinical Chemistry 1998 44 991-1001.
29. Stadil F & Rehfeld JF. Determination of gastrin in serum. An evaluation of the reliability of a radioimmunoassay. Scandinavian Journal of Gastroenterology 1973 8 101-112.
30. Medhus AW, Lofthus CM, Bredesen J & Husebye E. Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterology and Motility 2001 13 179-185. (doi:10.1046/j.1365-2982.2001.00249.x)
31. Miceli JN, Aravind MK, Cohen SN & Done AK. Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography. Clinical Chemistry 1979 25 1002-1004.
32. Sonne DP, Hare KJ,Martens P, Rehfeld JF, Holst JJ, Vilsbøll T & Knop FK. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. American Journal of Physiology. Gastrointestinal and Liver Physiology 2013 304 G413-G419. (doi:10.1152/ajpgi.00435.2012)
33. Lindgren O, Carr RD, Holst JJ, Deacon CF & Ahrén B. Dissociated incretin hormone response to protein versus fat ingestion in obese subjects. Diabetes, Obesity & Metabolism 2011 13 863-865. (doi:10.1111/j.1463-1326.2011.01420.x)
34. Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF & Ahrén B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. American Journal of Physiology. Endocrinology and Metabolism 2008 295 E779-E784. (doi:10.1152/ajpendo.90233.2008)
35. Alssema M, Rijkelijkhuizen JM, Holst JJ, Teerlink T, Scheffer PG, Eekhoff EM, Gastaldelli A, Mari A, Hart LM, Nijpels G et al. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. European Journal of Endocrinology 2013 169 421-430. (doi:10.1530/EJE-13-0487)
36. Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D, Weiss B, Larson P, Gutierrez M, Jiang G et al. Dipeptidyl peptidase-4 inhibitors administered in combination withmetformin result in an additive increase in theplasma concentrationof activeGLP-1. ClinicalPharmacology and Therapeutics 2010 88 801-808. (doi:10.1038/clpt.2010.184)
37. Matikainen N, Bogl LH, Hakkarainen A, Lundbom J, Lundbom N, Kaprio J, Rissanen A, Holst JJ & Pietiläinen KH. GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance. Diabetes Care 2014 37 242-251. (doi:10.2337/dc13-1283)
38. Kjems LL, Holst JJ, Vølund A & Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on b-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003 52 380-386. (doi:10.2337/diabetes.52.2.380)
39. Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G, Mari A & Ahrén B. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. Journal of Clinical Endocrinology and Metabolism 2011 96 2519-2524. (doi:10.1210/jc.2011-0266)
40. Nilsson M, Holst JJ & Björck IM. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. American Journal of Clinical Nutrition 2007 85 996-1004.
41. Fieseler P, Bridenbaugh S, Nustede R, Martell J, Orskov C, Holst JJ & Nauck MA. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. American Journal of Physiology 1995 268 E949-E955.
42. Boden G. Nutritional effects of fat on carbohydrate metabolism. Baillière's Clinical Endocrinology and Metabolism 2003 17 399-410.
43. Ahrén B, Holst JJ & Deacon CF. An incretin effect exists after amino acids administration in humans; effects on incretin hormones and insulin after oral vs intravenous amino acids [abstract]. Diabetes 2014 64 (Suppl 1) 189-OR.
44. Dunning BE, Foley JE & Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005 48 1700-1713. (doi:10.1007/s00125-005-1878-0)
45. Keshavrzzian A, Dunne M& Iber FL. Gallbladder volume and emptying in insulin-requiring male diabetics. Digestive Diseases and Sciences 1987 32 824-828. (doi:10.1007/BF01296703)
46. De Boer SY, Masclee AA, Jebbink MC, Schipper J, Lemkes HH, Jansen JB & Lamers CB. Effect of acute hyperglycaemia on gallbladder contraction induced by cholecystokinin in humans. Gut 1993 34 1128-1132. (doi:10.1136/gut.34.8.1128)
47. Rayner CK, Samsom M, Jones KL & Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001 24 371-381. (doi:10.2337/diacare.24.2.371)
48. De Boer SY, Masclee AA, Lam WF, Jansen JB & Lamers CB. Effect of intravenous glucose on intravenous amino acid-induced gallbladder contraction and CCK secretion. Digestive Diseases and Sciences 1994 39 268-274. (doi:10.1007/BF02090196)
49. Gielkens HA, Lam WF, Coenraad M, Frölich M, van Oostayen JA, Lamers CB & Masclee AA. Effect of insulin on basal and cholecystokinin-stimulated gallbladder motility in humans. Journal of Hepatology 1998 28 595-602. (doi:10.1016/S0168-8278(98) 80282-1)
50. Rushakoff RA, Goldfine ID, Beccaria LJ, Mathur A, Brand RJ & Liddle RA. Reduced postprandial cholecystokinin (CCK) secretion in patients with noninsulin-dependent diabetes mellitus: evidence for a role for CCK in regulating postprandial hyperglycemia. Journal of Clinical Endocrinology and Metabolism 1993 76 489-493.